financial assistance for cbd oil

Financial assistance for cbd oil

Looking for CBD financial assistance? We can help with that.

We believe that everybody should have access to high quality CBD, especially those with medical needs. That’s why we created our CBD assistance program for those in need of financial help.

We offer discounts for the following:

  • Income based assistance for those with a medical need – discount varies based on income
  • Income based assistance for those living under the poverty level – verification required
  • 15% Discounts for veterans and active military.
  • Individuals on long term disability

Our CBD financial assistance program offers discounts up to 40%.

Each program requires you to simply provide one form of documentation about your status or circumstance and a short letter explaining why you need assistance.

Our CBD discounts vary based on need and income level.

Use the form below to start the application process.

Let us know about your need and why you feel like you qualify. We will reply back within 2 business days to obtain any additional information needed.

Note: Discounts are only valid on full priced items and can not be combined with any other offers. We reserve the rite to revoke discount access for abuse. Discount is good for personal, and immediate family use only.


CBD Financial Assistance For All

As Hemp Daddy’s continues to grow we hope to be able to provide financial assistance for ALL those in need. We also strive to make our products more affordable, and will continue to decrease our prices as we achieve economies of scale and hemp prices continue to come down.

We know that CBD is expensive, but we believe it’s powerful medicine and should be accessible to everybody.

As our business continues to grow, so will our CBD financial assistance program. We look forward to serving you and your loved ones.

Financial assistance for cbd oil

Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on

Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy

Abstract: Recent approval of Epidiolex (pharmaceutical cannabidiol/CBD) for the treatment of Lennox Gastaut syndrome (LGS) and Dravet syndrome highlights a therapeutic efficacy of CBD in the treatment of epilepsy.

A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health

Introduction. Despite widespread legalization, the impact of medicinal cannabis use on patient level health and quality of life has not been carefully evaluated. The objective of this study was to

Questions & Answers

  • Fund and collect research to learn more about cannabis and its effects while legitimizing the therapy
  • Educate consumers and healthcare professionals on accumulated research
  • Assist clients in choosing a product of quality and helping to direct them where to purchase
  • Offer one on one support with clients worldwide throughout their cannabinoid therapy
  • Need help choosing a product
  • Need help with how much to take and how often
  • Would like to learn more about cannabinoid therapy
  • Are interested in taking part in cannabinoid research
  • Have doubts, concerns or questions regarding cannabinoid therapy

Cannabidiol, or CBD, is one of at least 80 cannabinoids unique to cannabis. Reported benefits of CBD in cannabinoid therapy include being an anticonvulsant, anti-inflammatory, immunosuppressive, anti-nausea, anti-vomiting, anti-anxiety, antidepressant, antipsychotic, antioxidant, anti-tumoral, neuroprotective agent, anti-degenerative agent, and spermatogenesis agent. Check out our Guide to CBD for more information.

Tetrahydrocannabinol, or THC, is the principal constituent (or cannabinoid) of the cannabis plant and has psychoactive effects. Reported benefits of THC in cannabinoid therapy include pain relief, appetite stimulation, sleep aid, anti-nausea, anti-vomiting, and more. THC is available only in jurisdictions that have legalized it for medical or recreational purposes.

Cannabinoid therapy has been reported to be beneficial for a number of conditions which makes it a potential option for many. We have over 600 peer-reviewed research articles in our Research Library where you can learn more.

Realm of Caring assists pediatric and adult clients, as well as pets.

Two identical individuals with the same condition taking the same product can have two different outcomes or results, so it is difficult to suggest a condition-specific product. Therefore, this process may involve some trial and error to determine what is the right product or combination of products for you.

See also  cbd oil for diabetez

The best option to research specific medical conditions and different cannabinoids is to visit the Research Library where you’ll find over 600 peer-reviewed journal articles in relation to medical cannabis. You can enter in the appropriate keywords (i.e. diagnosis and cannabis/ CBD/ THC/ THC-A).

Realm of Caring does its best to rely on our collective data and guide you in getting started. There are many anecdotal stories that you can find on our client spotlight page.

There is extensive research on the safety and toxicology of cannabinoids and there are several studies that suggest that cannabinoids are well-tolerated and safe for humans at high doses. However, there can be potential drug interactions. In addition, there is not enough evidence to determine the absolute safety of using cannabis/hemp/CBD for special populations (i.e. pregnant/nursing, some psychiatric conditions,etc.) Give us a call to discuss in detail (719) 347-5400, option 1.

To discuss your situation with a Realm of Caring Care Specialist, please call (719) 347-5400 option 1 or email [email protected]

As laws vary from country to country, we suggest contacting either product manufacturers or authorities in your country or the country you may wish to visit.

Our Care Specialists may be able to locate a retailer that could sell products in a specific country

We understand cannabinoid therapy can be overwhelming; that is why we are here to help. We’ve made a Getting Started Video and can help you locate a suggested product .

Once you determine a product, there are several ways to administer cannabis: sublingual, oral, topical, transdermal, vaporized, and more. For optimal results, we suggest you are as accurate and consistent as possible when administering any oil (i.e. using oral syringes). The amount that an individual takes in a day varies based upon weight, condition, and brain chemistry. Please visit the Dosing and Administration Guidelines for more information. We recommend scheduling a one-on-one with a Care Specialist in order to speak in-depth about your specific condition, call (719) 347-5400, option 1.

CBD derived from hemp (with less than 0.3% THC) can be purchased in select retail outlets as well as online. Please follow the links of our RoC Approved Product Lines to learn more. Medical cannabis products that contain more than 0.3% THC must be purchased from a medical or recreational dispensary.

CBD products containing less than 0.3% THC can be shipped nationally and in some cases internationally from the product company. Realm of Caring does not sell or distribute any products.

You are welcome to seek out other forms of high-CBD therapy besides the products we recommend. When doing so, be sure to connect with a manufacturer that can provide test results. Some important factors to consider are:

  • Product is free of fungus, molds, mildews, or other harmful ingredients including pesticides, heavy metals, and residual solvents.
  • You also want to know the exact concentration of cannabinoids so that you can administer it properly.
  • Check out our Product Quality Checklist for more information

In 2019 the TSA confirmed travel within the United States with CBD products containing less than 0.3% THC are allowed. For more information visit the TSA’s website.

When traveling abroad, you will want to check the rules and regulations of the country you are traveling to. Even if CBD may be bought or taken into a country, the legal amount of THC allowed in CBD products can vary depending on which country you are in.

It is a possibility. This is not a cut and dry answer because CBD products have the potential of containing trace amounts of THC – the psychoactive chemical compound in the plant. THC can accumulate in the fat, even in trace quantities, and cause a positive result in a drug screening test.

It is important to note that CBD and/or THC may cross through the placenta and therefore fetal exposure risks can not be ruled out. There are currently no studies supporting the use of CBD and other cannabis products in pregnancy. There are studies concluding that high-THC cannabis use can have negative effects on the fetal developing brain and body. We encourage you to speak with a doctor or midwife for further advice.

See also  uses for cbd oils and eye health

See our blog, Cannabinoid Therapy for Pets for more detailed information about how cannabinoid therapy may benefit your furbaby. As well, some of the companies we support carry CBD pet-specific products that aid in their health and wellness.

Researchers recommend clinical trials for CBD to prevent COVID-19 based on promising animal data

An interdisciplinary team of researchers from the University of Chicago has found evidence that cannabidiol (CBD), a product of the cannabis plant, can inhibit infection by SARS-CoV-2 in human cells and in mice.

The study, published on January 20, 2022, in Science Advances, found CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of medical records of patients taking the FDA-approved drug for treating epilepsy. The researchers now say that clinical trials should be done to determine whether CBD could eventually be used as a preventative or early treatment for COVID-19. They caution, however, that the COVID-blocking effects of CBD come only from a high purity, specially formulated dose taken in specific situations. The study’s findings do not suggest that consuming commercially available products with CBD additives that vary in potency and quality can prevent COVID-19.

Scientists have been looking for new therapies for people infected by the coronavirus and emerging variants, especially those who lack access to vaccines, as the pandemic continues across the country and world and as breakthrough infections become more common.

CBD: An unexpected avenue for fighting COVID-19

The idea to test CBD as a potential COVID-19 therapeutic was serendipitous. “CBD has anti-inflammatory effects, so we thought that maybe it would stop the second phase of COVID infection involving the immune system, the so-called ‘cytokine storm.’ Surprisingly, it directly inhibited viral replication in lung cells,” said Marsha Rosner, PhD, Charles B. Huggins Professor in the Ben May Department of Cancer Research and a senior author of the study.

To see this effect, the researchers first treated human lung cells with a non-toxic dose of CBD for two hours before exposing the cells to SARS-CoV-2 and monitoring them for the virus and the viral spike protein. They found that, above a certain threshold concentration, CBD inhibited the virus’ ability to replicate. Further investigation found that CBD had the same effect in two other types of cells and for three variants of SARS-CoV-2 in addition to the original strain.

CBD did not affect the ability of SARS-CoV-2 to enter the cell. Instead, CBD was effective at blocking replication early in the infection cycle and six hours after the virus had already infected the cell.

Like all viruses, SARS-CoV-2 affects the host cell by hijacking its gene expression machinery to produce more copies of itself and its viral proteins. This effect can be observed by tracking virus-induced changes in cellular RNAs. High concentrations of CBD almost completely eradicated the expression of viral RNAs. It was a completely unexpected result.

“We just wanted to know if CBD would affect the immune system,” Rosner said. “No one in their right mind would have ever thought that it blocked viral replication, but that’s what it did.”

The researchers showed that the mechanism by which CBD blocks SARS-CoV-2 replication involves CBD activation of one of the host cell stress responses and generation of interferons, an antiviral cell protein.

Real world data: Patients taking CBD test positive for COVID-19 at lower rates

The researchers wanted scientific data to show that CBD prevents viral replication in live animals. The team showed pretreatment with CBD for one week prior to infection with SARS-CoV-2 suppressed infection both in the lung and the nasal passages of mice. “These results provide major support for a clinical trial of CBD in humans,” said Rosner.

And the success of CBD wasn’t limited to the laboratory: An analysis of 1,212 patients from the National COVID Cohort Collaborative revealed that patients taking a medically prescribed oral solution of CBD for the treatment of epilepsy tested positive for COVID-19 at significantly lower rates than a sample of matched patients from similar demographic backgrounds who were not taking CBD.

See also  square beta program for cbd oil sales

The potential for CBD to treat patients recently exposed to or infected by SARS-CoV-2 does not precede the first lines of defense against COVID-19, which are to get vaccinated and follow existing public health guidelines for masking in indoor spaces and social distancing. But the published results offer a potential new therapeutic, something still needed as the pandemic rages on.

“A clinical trial is necessary to determine whether CBD is really effective at preventing or suppressing SARS-CoV-2 infection, but we think this may have potential as a prophylactic treatment,” said Rosner. “Maybe you’re in a hot spot or you think you might have been exposed or you’ve just tested positive — that’s where we think CBD might have an effect.”

Not your dispensary’s CBD

The research team emphasized that the COVID-blocking effects of CBD were confined strictly to high purity, high concentrations of CBD. Closely related cannabinoids such as CBDA, CBDV and THC, the psychoactive element enriched in marijuana plants, did not have the same power. In fact, combining CBD with equal amounts of THC actually reduced the efficacy of CBD.

“Going to your corner bakery and buying some CBD muffins or gummy bears probably won’t do anything,” said Rosner. “The commercially available CBD powder we looked at, which was off the shelf and something you could order online, was sometimes surprisingly of high purity but also of inconsistent quality. It is also hard to get into an oral solution that can be absorbed without the special, FDA-approved formulation,” Rosner said.

Furthermore, CBD use is not without potential risks. It appears to be extremely safe when consumed in food or drink, but methods of use such as vaping can have negative side effects, including potential damage to the heart and lungs. It’s also not well studied in certain populations, such as pregnant people, and so should be used only under the supervision of a physician and with caution.

While the study’s results are exciting, additional study is needed to determine the precise dosing of CBD that is effective at preventing SARS-CoV-2 infection in humans as well as its safety profile and any potential side effects.

“We are very eager to see some clinical trials on this subject get off the ground,” Rosner said. “Especially as we are seeing that the pandemic is still nowhere near the end — determining whether this generally safe, well-tolerated, and non-psychoactive cannabinoid might have anti-viral effects against COVID-19 is of critical importance.”

Rosner was also pleased that this research project was a case study in the power of scientific collaboration by bringing together a highly interdisciplinary group of researchers. Senior authors listed on the paper came from three different research universities and from departments as diverse as microbiology, molecular engineering, cancer biology and chemistry.

“This was truly a team-science effort, and that’s something that really excites me,” said Rosner. “From clinicians to David Meltzer’s group who did the patient analysis to virologists like Glenn Randall, and it goes on and on. This is the way science should be carried out.”

The study, “Cannabidiol Inhibits SARS-CoV-2 Replication through Induction of the Host ER Stress and Innate Immune Responses,” was supported by a BIG Vision grant from the University of Chicago, the National Institutes of Health (R01 GM121735, R01 CA184494, R01 AI137514, R01 AI127518, R01 AI134980, R01 CA219815, R35 GM119840, P30 CA014599), and the Harry B. and Leona M Helmsley Charitable Trust. Additional authors include Long Chi Nguyen, Dongbo Yang, Thomas J. Best, Nir Drayman, Adil Mohamed, Christopher Dann, Diane Silva, Lydia Robinson-Mailman, Andrea Valdespino, Letícia Stock, Eva Suárez, Krysten A. Jones, Saara-Anne Azizi, James Michael Millis, Bryan C. Dickinson, Savaş Tay, Scott A. Oakes, and David O. Meltzer of the University of Chicago; Vlad Nicolaescu, Haley Gula, and Glenn Randall of UChicago and Argonne National Laboratory; Divayasha Saxena, Jon D. Gabbard, Jennifer K. Demarco, William E. Severson, Charles D. Anderson, and Kenneth E. Palmer of the University of Louisville; Shao-Nong Chen, Takashi Ohtsuki, John Brent Friesen, and Guido F. Pauli of the University of Illinois at Chicago; and the National COVID Cohort Collaborative Consortium.